Navigation Links
TransMessenger Transfection Reagent

For transfection of cells with siRNA in RNAi procedures Features and benefits
  • Efficient transfection of siRNA for effective gene silencing
  • Quick and easy setup
  • Ready-to-use reagent
  • Tested for absence of RNase activity
Principle TransMessenger Transfection Reagent facilitates effective gene silencing in RNAi procedures by providing efficient transfection of siRNA into eukaryotic cells using a fast and easy procedure (see figure "Efficient Transfection of Primary Neuronal Cells Using QIAGEN siRNA and TransMessenger Reagent"). The reagent is a lipid-based formulation that is used in conjunction with a specific RNA-condensing enhancer and an optimized buffer to form siRNA-TransMessenger Reagent complexes that are efficiently transferred into eukaryotic cells. Strict quality control is performed to test for absence of RNase activity, lot-to-lot consistency, and low endotoxin levels (=10 EU/ml). Our rigorous standards eliminate reagent variables that can adversely affect the efficiency of siRNA transfection. Efficient Transfection of Primary Neuronal Cells Using QIAGEN siRNA and TransMessenger Reagent Primary neuronal cells from rats were transfected with a control nonspecific siRNA or an siRNA directed against microtubule-associated protein 2 (MAP2) using TransMessenger Transfection Reagent. Two days after transfection, cells were fixed, permeabilized, and stained using mouse monoclonal anti-MAP2 antibodies and Alexa Fluor 488-conjugated goa t anti-mouse secondary antibody (a-MAP2) and Alexa Fluor 594-conjugated phalloidin, which binds to f-actin and serves here as an expression control.

Data kindly provided by A.M. Krichevsky and K.S. Kosik, Brigham and Womens Hospital, Harvard Medical School, Boston, MA (from Krichevsky, A.M., and Kosik, K.S. (2002) RNAi functions in cultured mammalian neurons. Proc. Natl. Acad. Sci. USA 99, 11926. Copyright 2002 National Academy of Sciences, U.S.A.)

Procedure All TransMessenger Reagent components are provided as ready-to-use solutions. To generate TransMessenger-RNA transfection complexes, simply mix your siRNA with Enhancer R and Buffer EC-R and incubate for 5 minutes at room temperature, then add TransMessenger Reagent and incubate for a further 10 minutes. The complexes are mixed with medium and added directly to the cells. Following a 3 hour incubation, the medium is changed and the cells are incubated until they are ready for analysis.

Optimal transfection results are achieved using high-purity siRNA. The QIAGEN siRNA Oligo Synthesis Service offers custom siRNA oligos, a range of library siRNAs that target specific genes, non-silencing control siRNAs, and a set of siRNAs targeting genes linked with cancer; the Cancer siRNA Oligo Set Version 1.0.
Since the amount of siRNA used is a critical factor for successful transfection, we recommend optimizing the amounts of siRNA and TransMessenger Transfection Reagent for every cell type-siRNA combination. To facilitate this, the reagent is provided with guidelines and starting points for optimization of RNAi experiments.

App lications TransMessenger Reagent has been used to mediate successful RNAi in several studies using different cell types. For an up-to-date list of references and the latest developments in QIAGEN products for RNAi visit the Transfection Tools site at www.qiagen.com/transfectiontools.


'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Efficient DNA transfection of primary CNS neurons using TransMessenger Transfection Reagent
2. TransMessenger Transfection Reagent Handbook
3. TransMessenger Transfection Reagent
4. Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN siRNA and TransMessenger Transfection Reagent*
5. Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell Line
6. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
7. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
8. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
9. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
10. Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells
11. Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection of Mammalian Cells
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... and solutions to the healthcare market. The company's primary focus is on new ... and marketing strategies that are necessary to help companies efficiently bring their products ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):